title: [Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].
abstract: The hyperactivation of renin-angiotensin-aldosterone system (RAAS) underlies the development and the progression of arterial hypertension and chronic kidney diseases. Aldosterone is the main unit of RAAS and self-sufficient predictor of the development of cardiovascular events. In this study, the angiotensin receptor blocker valsartan, ACE inhibitor enalapril, and direct renin inhibitor aliskiren were used for the correction of blood pressure and aldosterone levels in patients with hypertension and chronic kidney diseases. The data obtained suggest that the proposed complex therapy provides the most complete blood pressure reduction and aldosterone level correction (as evidence of RAAS activity recovery), greatly improves the prognoses, and ensures maximum nephroprotection in the patients with arterial hypertension and chronic kidney diseases.
authors.forename: O V
authors.initials: OV
authors.lastname: Dralova
authors.forename: M L
authors.initials: ML
authors.lastname: Maksimov
authors.forename: E A
authors.initials: EA
authors.lastname: Derbentseva
authors.forename: A S
authors.initials: AS
authors.lastname: Ermolaeva
authors.forename: A K
authors.initials: AK
authors.lastname: Starodubtsev
mesh_terms: D000368:Aged; D000450:Aldosterone / Q000097:blood*; D000577:Amides / Q000494:pharmacology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000494:pharmacology; D015415:Biomarkers; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000494:pharmacology; D005260:Female; D005650:Fumarates / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007190:Indapamide / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013777:Tetrazoles / Q000494:pharmacology; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology; D000068756:Valsartan
chemical_list: D000577:Amides; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D015415:Biomarkers; D005650:Fumarates; D000451:Mineralocorticoid Receptor Antagonists; D013777:Tetrazoles; D000450:Aldosterone; C446481:aliskiren; D004656:Enalapril; D000068756:Valsartan; D007190:Indapamide; D014633:Valine